Denali Therapeutics Inc. (DNLI) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Denali Therapeutics Inc. Do?
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics Inc. (DNLI) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Ryan J. Watts and employs approximately 430 people. With a market capitalization of $3.1B, DNLI is one of the notable companies in the Healthcare sector.
Denali Therapeutics Inc. (DNLI) Stock Rating — Reduce (April 2026)
As of April 2026, Denali Therapeutics Inc. receives a Reduce rating with a composite score of 33.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DNLI ranks #1,991 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Denali Therapeutics Inc. ranks #212 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
DNLI Stock Price and 52-Week Range
Denali Therapeutics Inc. (DNLI) currently trades at $19.23. The stock lost $0.06 (0.3%) in the most recent trading session. The 52-week high for DNLI is $23.77, which means the stock is currently trading -19.1% from its annual peak. The 52-week low is $10.57, putting the stock 81.9% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.
Is DNLI Overvalued or Undervalued? — Valuation Analysis
Denali Therapeutics Inc. (DNLI) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.04x, versus the sector average of 2.75x.
At current multiples, Denali Therapeutics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Denali Therapeutics Inc. Profitability — ROE, Margins, and Quality Score
Denali Therapeutics Inc. (DNLI) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -48.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -42.9% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
DNLI Debt, Balance Sheet, and Financial Health
Denali Therapeutics Inc. has a debt-to-equity ratio of 13.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.16x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $91M.
DNLI has a beta of 1.44, meaning it is more volatile than the broader market — a $10,000 investment in DNLI would be expected to move 44.4% more than the S&P 500 on any given day. The stability factor score for Denali Therapeutics Inc. is 40/100, reflecting average volatility within the normal range for its sector.
Denali Therapeutics Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Denali Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-2.97. Net income for the quarter was $-491M. Operating income came in at $-541M.
In FY 2025, Denali Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-2.97. Net income for the quarter was $-513M. Operating income came in at $-555M.
In Q3 2025, Denali Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.74. Net income for the quarter was $-127M. Operating income came in at $-137M.
In Q2 2025, Denali Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.72. Net income for the quarter was $-124M. Operating income came in at $-135M.
Over the past 8 quarters, Denali Therapeutics Inc. has experienced revenue contraction from $0 to $0. Investors analyzing DNLI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
DNLI Dividend Yield and Income Analysis
Denali Therapeutics Inc. (DNLI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
DNLI Momentum and Technical Analysis Profile
Denali Therapeutics Inc. (DNLI) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
DNLI vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Denali Therapeutics Inc. (DNLI) ranks #212 out of 838 stocks based on the Blank Capital composite score. This places DNLI in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing DNLI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DNLI vs S&P 500 (SPY) comparison to assess how Denali Therapeutics Inc. stacks up against the broader market across all factor dimensions.
DNLI Next Earnings Date
No upcoming earnings date has been announced for Denali Therapeutics Inc. (DNLI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy DNLI? — Investment Thesis Summary
The quantitative profile for Denali Therapeutics Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. Price momentum is positive at 65/100, suggesting the trend favors buyers.
In summary, Denali Therapeutics Inc. (DNLI) earns a Reduce rating with a composite score of 33.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DNLI stock.
Related Resources for DNLI Investors
Explore more research and tools: DNLI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DNLI head-to-head with peers: DNLI vs AZN, DNLI vs SLGL, DNLI vs VMD.